Consistent with the improved colitis clinical symptoms, GTA treatment decreased the number of infiltrating T cells and macrophages in the colon and increased the number of IgA+ B cells and IgA+ plasma cells as well as the secretion of IgA in the stool of Hif1a cKO mice (Fig. 6H–J). This evidence concerns the gene CD79A and colitis.